Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Elvitegravir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    56 result(s) found for: Elvitegravir. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-004736-23 Sponsor Protocol Number: GS-US-183-0130 Start Date*: 2015-02-18
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subj...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005116-10 Sponsor Protocol Number: ELVIs Start Date*: 2014-04-10
    Sponsor Name:Dr. Daniel Podzamczer Palter (Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge).
    Full Title: Elvitegravir concentrations in seminal plasma in HIV-1 infected patients (?ELVIs Study?)
    Medical condition: HIV-1 positive patients
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004015-36 Sponsor Protocol Number: IN-IT-236-1320 Start Date*: 2015-02-16
    Sponsor Name:AZIENDA OSPEDALIERA SAN PAOLO
    Full Title: Role of a switch strategy to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (QUAD) on HIV reservoir and immune activation.
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001969-16 Sponsor Protocol Number: GS-US-183-0160 Start Date*: 2013-10-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10020192 HIV-1 LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000725-37 Sponsor Protocol Number: GS-US-183-0149 Start Date*: 2015-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volu...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004458-27 Sponsor Protocol Number: GS-US-292-0104 Start Date*: 2013-05-13
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir D...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) IT (Completed) SE (Completed) NL (Prematurely Ended) GB (Completed) DE (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000102-37 Sponsor Protocol Number: GS-US-292-0111 Start Date*: 2013-06-03
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir D...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) IT (Completed) AT (Completed) DE (Completed) NL (Completed) PT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003917-29 Sponsor Protocol Number: GS-US-183-0152 Start Date*: 2008-11-11
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002855-27 Sponsor Protocol Number: IN-CA-311-3963/CTN299 Start Date*: 2018-01-22
    Sponsor Name:UNIVERSITY HEALTH NETWORK
    Full Title: BonE health in ageING Women: Improvement or prevention of changes in Bone Mineral Density by Switching Antiretroviral Agents. Is there an optimal time to intervene?
    Medical condition: HIV infection and menopause
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002830-19 Sponsor Protocol Number: GS-US-292-0117 Start Date*: 2013-11-27
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alaf...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004225-26 Sponsor Protocol Number: GS-US-183-0145 Start Date*: 2008-08-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou...
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002780-26 Sponsor Protocol Number: GS-US-292-0106 Start Date*: 2015-01-27
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in H...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002712-32 Sponsor Protocol Number: GS-US-292-1826 Start Date*: 2015-11-16
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/T...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000313-40 Sponsor Protocol Number: GS-US-236-0112 Start Date*: 2015-01-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1...
    Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002713-30 Sponsor Protocol Number: GS-US-292-1825 Start Date*: 2016-04-05
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection in Subjects on Chronic Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002006-39 Sponsor Protocol Number: ESTER Start Date*: 2016-11-14
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection
    Medical condition: Treatment of HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002711-15 Sponsor Protocol Number: GS-US-292-1823 Start Date*: 2015-11-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegr...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001193-34 Sponsor Protocol Number: STRIB-PEP Start Date*: 2014-07-16
    Sponsor Name:Fundació Clínic per a la recerca biomèdica
    Full Title: COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS...
    Medical condition: Prophilaxis VIH infecction post accidental exposition (PPE)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016758-42 Sponsor Protocol Number: GS-US-236-0103 Start Date*: 2010-06-28
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) BE (Completed) NL (Completed) AT (Completed) ES (Prematurely Ended) DK (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005550-18 Sponsor Protocol Number: 1439A-024 Start Date*: 2015-08-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed) ES (Ongoing) FR (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA